Imetelstat:第一次批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|August 20, 2024
概括
伊梅特尔斯塔特 (RYTELOTM) 是一种新型的端粒酶抑制剂,已获批准用于骨髓质疏松症候群 (MDS). 这一里程碑为成年患者提供了新的治疗选择,这些患者患有输血依赖性贫血,并没有对其他疗法做出反应.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨髓发育综合征 (MDS) 是一组克隆性造血干细胞疾病.
- 输血依赖性贫血是低风险MDS的常见并发症.
- 现有的治疗方法,如红色素形成刺激剂 (ESA),对一些患者有局限性.
研究的目的:
- 总结一下imetelstat.stat的发展里程碑.
- 为了突出最近美国FDA对特定MDS患者群体的imetelstat的批准.
主要方法:
- 审查imetelstat的发展路径.
- 对临床试验数据的分析导致监管提交.
- 监管审查过程的总结,以获得imetelstat的批准.
主要成果:
- 一种寡核酸端粒酶抑制剂Imetelstat在治疗低风险MDS的输血依赖性贫血方面表现出有效性.
- 美国FDA在2024年6月批准,用于患有低至中等-1风险MDS的成年患者.
- 患者包括那些对ESA无反应,失去反应或不符合条件的患者.
结论:
- 伊梅特尔斯塔特 (RYTELOTM) 代表了MDS治疗的重大进展.
- 该批准为MDS患者的特定子集提供了一种新的治疗选择.
- 这标志着imetelstat的首次批准,解决了MDS管理中的未满足需求.
相关概念视频
First Pass Effect
10.5K
Presystemic elimination, or the first-pass effect, is the metabolism of drugs that reduces their effective concentration at the site of action. Apart from the first-pass effect, the systemic bioavailability of the drug is also reduced by other factors, including incomplete absorption or chemical degradation of drugs.
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
10.5K
FDA Approved Drugs: Changes to Approved Drugs
343
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Automated Microbial Diagnostics
77
Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
77


